Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Windtree Therapeutics, Inc.

$0.01

0 (-0.7%)

D 28Pipeline Score Fair Value Biotech · Clinical
Market Cap
3.15 M
EPS
-218.81
P/E Ratio
-
Value Trade
926.67
SEC Financials
Q3 2025

  • Dilution Risk

    95%

  • R&D Expenses

    1.90 M

  • Total Assets

    15.98 M

  • Total Liabilities

    27.58 M

  • Equity

    -11.61 M

  • D/E Ratio

    12,345

-78.43 %
Week
-90.76 %
1 Month
-85.69 %
3 Month
-97.65 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Critical

  • Cash Position

    204.00 K

  • Monthly Burn

    6.63 M

  • Runway

    0 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Nov 19, 2025
Overview
Volume
64.40 K
52 Week Range
0.10 - 572.50
% held by Insiders
0.08 %
% held by Institutions
6.04 %
Enterprise Value
14.79 M
Total Shares
28.66 M
Short %
124.02 %
Float Shares
28.65 M
Company Description

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-08-11
istaroxime
phase 2 data readout
Phase 2
—
–
–
–
2025-08-11
istaroxime
phase 2 data readout
Phase 2
—
–
–
–
2025-08-11
istaroxime
phase 2 data readout
Phase 2
—
–
–
–
Unlock Historical Catalyst data
Drug Pipeline Intelligence
D28
Pipeline Score
$4M
Pipeline Value
Fair Value
Valuation Signal
6
Drugs Scored
1.2x
rNPV / MCap
Top 30%
Micro Cap
(rank 639 of 912)
Percentile Rank
Windtree Therapeutics, Inc. faces pipeline headwinds (28/100), with $1.3B risk-adjusted pipeline value, led by Lucinactant in COVID-19 (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Lucinactant
Small molecule		COVID-19Phase 2NCT0438967121% $525M COMPLETED 20 - -Feb 20, 2022 -Jun 23, 2023
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
AEROSURF
Respiratory Distress Syndrome (RDS) in Premature Infants
Phase 2b
2017-06-29

n CPAP failure rates: 25 minute 44 percent, 50 minute 44 percent, control 44 percent, 50 minute no interruptions 31 percent, control no interruptions 44 percent; absolute reduction: 13 percent; relative reduction: 30 percent

Read More

Windtree Announces Top-Line Results from AEROSURF Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants -Company to Hol d Conference Call Today at 4:30 p.m. EDT- WARRINGTON

Read More
AEROSURF
Respiratory Distress Syndrome (RDS) in Premature Infants
Phase 2b
2017-06-29

n CPAP failure rates: 25 minute 44 percent, 50 minute 44 percent, control 44 percent, 50 minute no interruptions 31 percent, control no interruptions 44 percent; absolute reduction: 13 percent; relative reduction: 30 percent

Read More

Windtree Announces Top-Line Results from AEROSURF Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants -Company to Hol d Conference Call Today at 4:30 p.m. EDT- WARRINGTON

Read More
AEROSURF
Respiratory Distress Syndrome (RDS) in Premature Infants
Phase 2b
2017-06-29

n CPAP failure rates: 25 minute 44 percent, 50 minute 44 percent, control 44 percent, 50 minute no interruptions 31 percent, control no interruptions 44 percent; absolute reduction: 13 percent; relative reduction: 30 percent

Read More

Windtree Announces Top-Line Results from AEROSURF Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants -Company to Hol d Conference Call Today at 4:30 p.m. EDT- WARRINGTON

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in WINT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
WINT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How WINT ranks across every disease it competes in
Competitive Position is a premium feature
See how WINT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial